☑ Cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem ☑ Cefepime-taniborbactam was well-tolerated with similar safety profile to meropenem ☑ NDA submission planned Q4'22

@Venatorx, @MelintaTx and Menarini Group are thrilled to announce positive Phase 3 Cefepime-Taniborbactamin study results for cUTI in the New England Journal of Medicine (@NEJM) #antibioticresistance, #antibiotic, #AMR, #superbug

Venatorx selects Menarini Group to commercialize Cefepime-Taniborbactamin in 96 countries in Europe, Latin America, Middle East, Turkey, N Africa and CIS. #antibioticresistance, #antibiotic, #AMR, #superbug

We're elated to announce a licensing agreement with @Melinta Therapeutics to commercialize Cefepime-Taniborbactam for cUTI and HABP/VABP in the US #antibioticresistance, #antibiotic, #AMR, #superbug

#IDweek2023: cefepime-taniborbactam, an investigational antibacterial agent, demonstrated higher in vitro activity vs antibiotics against clinically significant gram-negative bacteria isolated from #cancer patients at @MDAnderson #cancer #StandUptoCancer

Venatorx announces its 3rd partnership with @BARDA to support its oral antimicrobial candidate through a Phase 3 clinical trial. If @US_FDA-approved, this product could reduce hospitalization time for patients and combat AMR infections.

We are excited to offer seven presentations on our novel antibiotics cefepime-taniborbactam and ceftibuten-ledaborbactam at @IDWeekmtg 2023, October 11-15 in Boston. Read more: #antibioticresistance, #antibiotic, #AMR, #superbug, #stopsuperbugs,

We are thrilled to be featured in @andyextance's @ChemistryWorld article on innovation in drug development for antibiotic resistance. Read: #antibioticresistance, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

RT @BioWorld: FDA accepts @VenatorxPharma NDA for cUTI antibiotic; PDUFA early 2024 #biotech #pharma

We are excited to announce #FDA acceptance and priority review of our #NDA for cefepime-taniborbactam to treat #cUTIs, including Pyelonephritis, in adults. The FDA has assigned a #PDUFA date of February 22, 2024. #AMR, #superbug #antibioticresistance

News: 2 recent publications show metallo-beta-lactamases(MBLs) increasing in US CRE isolates. CEO Chris Burns: "...it is essential that next generation antibiotics combat the evolving multi-drug resistant gram- infections, including #MBLs." #AMR, #superbug

Join us in welcoming our new Chairman of the Board, Tom Heyman. Tom brings a strong track record of success as an industry leader and board member, and we look forward to his expertise and guidance as we continue to advance our anti-infectives pipeline.

RT @WeFightAMR: Antimicrobial resistance or #AMR is a public health crisis. Globally, antibiotic-resistant infections killed 1.2 million pe…

RT @LabNotesPhilly: In this week's #LabNotes, @keystone_us adds 200K SF of #lab space to The Curtis, @LSGPA partners with #ArgoPond to spur…

Thank you! We look forward to our continued partnership in advancing these important medicines #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

We looking forward to our continued partnership in advancing these important medicines. #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

We are happy to be a part of this vital effort. #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

Spread the word: it's World Antimicrobial Awareness Week. We support Vivli's AMR Register for #AMR surveillance datasets to drive science & understanding. #WAAW2022 #AntibioticResistance #AWG_news #superbug #stopsuperbugs #saveantibiotics #AMRActionFund

It also noted this trend is worrisome since there are limited therapeutic options against MBL producers and more treatment options covering these and other resistant isolates are needed. 3/3

These data showed that ~20% of CRE are not carbapenemase producers and among CRE with carbapenemases, ~13% were metallo-beta lactases (MBL). 2/3

At @IDWeek2022, JMI’s poster #P664 announced US susceptibility results for carbapenem resistant Enterobacterales (CRE) in 2021. #antibiotic resistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund 1/3